Text Size

Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Teresa Hayes, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00616291
First received: February 14, 2008
Last updated: November 5, 2012
Last verified: November 2012
History of Changes
  Purpose

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.

PURPOSE: This phase I trial is studying the side effects of a peptide vaccine in treating patients with metastatic prostate cancer.


Condition Intervention Phase
Prostate Cancer
 Biological: NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine
 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Immunotherapy of Patients With Androgen-Independent Prostate Carcinoma Using NY-ESO-1/LAGE1 Peptide Vaccine (SPORE #: 11-01-30-14)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Baylor College of Medicine:

Primary Outcome Measures:
  • Tolerability [ Designated as safety issue: Yes ]
  • Toxicity [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Immunological response [ Designated as safety issue: No ]

Enrollment: 14
Study Start Date: April 2006
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group I
MHC Class I binding peptide at 1000 mcg
 Biological: NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine
Experimental: Group II
MHC Class II binding peptide at 1000 mcg
 Biological: NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine
Experimental: Group III
Combination MHC Class I and II binding peptide at 1000 mcg each
 Biological: NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine

Detailed Description:

OBJECTIVES:

Primary

  • Evaluate the safety and tolerance of NY-ESO-1/LAGE-1 class-I and class-II vaccine administered subcutaneously in patients with androgen-independent metastatic prostate cancer.

Secondary

  • Compare the response induced by immunotherapy with a combined class-I and class-II NY-ESO-1/LAGE-1 vaccine to responses obtained to either class I or class II peptides alone.
  • Evaluate whether the inclusion of class-II epitopes in a peptide vaccine will result in a better antitumor immune response than class-I epitopes alone.
  • Determine antitumor activity by antigen response assays including cytokine elaboration, changes in frequency of peripheral T cells that recognize tumor, and intra/peritumoral cellular infiltrates and cytokine expression in responding and nonresponding metastasis.

OUTLINE: Patients receive NY-ESO-1/LAGE-1 peptide vaccine subcutaneously every other week for 12 weeks in the absence of disease progression or unacceptable toxicity. The initial cohorts of patients are treated with one course of either MHC Class I-binding or MHC Class II-binding peptides. If these Class I or Class II binding peptides are safe individually, subsequent cohorts of patients with appropriate HLA type receive both types of peptides in combination.

After completion of study treatment, patients are followed every 6 months for up to 5 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed prostate cancer with evidence of progressive disease despite hormonal therapy (i.e., hormone-refractory prostate cancer)

    • Metastatic disease

    • Progressive disease defined by any of the following:

      • New bone lesion on bone scan
      • Progression of nodal or soft tissue as evidenced by standard radiographic methods, i.e., CT scan or MRI
      • A 50% increase in PSA level from the nadir PSA level confirmed twice and measured at least 2 weeks apart, with stable and measurable disease
  • Castrate serum levels of testosterone < 50 ng/dL

  • If patient was receiving anti-androgen therapy, in addition to luteinizing hormone-releasing hormone (LHRH) agonist therapy, the evidence of progressive disease should persist after a trial of anti-androgen withdrawal

    • Treatment with LHRH agonist to maintain androgen ablation must continue throughout this trial
  • Baseline PSA ≥ 10 ng/mL

  • All patients with androgen-independent prostate cancer and matched HLA typing are eligible for vaccination regardless of initial NY-ESO-1 expression status

    • Patients must be typed for HLA-DR4, DR13, DP4, or HLA-A2 haplotypes
  • No active brain metastases

PATIENT CHARACTERISTICS:

  • Zubrod performance status 0-2
  • Life expectancy ≥ 12 weeks
  • ANC ≥ 1,500/mm³
  • Hemoglobin ≥ 10 mg/dL
  • Platelet count ≥ 100,000/mm³
  • Bilirubin ≤ 1.5 mg/dL
  • SGPT ≤ 3 times upper limit of normal
  • Serum creatinine ≤ 2 mg/dL
  • Wiling to be followed at Baylor College of Medicine
  • No serious intercurrent medical illness
  • No history of primary or secondary immunodeficiency
  • No active systemic infection
  • No known hepatitis B surface antigen, hepatitis C, or HIV antibody positivity
  • No history of cardiac arrhythmia or ischemic heart disease

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • At least 6 weeks since prior immunotherapy (including anti-androgen therapy) and recovered
  • More than 28 days since prior chemotherapy
  • No concurrent immunosuppressive drugs such as systemic corticosteroids
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00616291

Locations
United States, Texas
Dan L. Duncan Cancer Center at Baylor College of Medicine
Houston, Texas, United States, 77030
Sponsors and Collaborators
Baylor College of Medicine
National Cancer Institute (NCI)
Investigators
Study Chair: Teresa G. Hayes, MD, PhD Veterans Affairs Medical Center - Houston
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Teresa Hayes, Associate Professor, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT00616291     History of Changes
Obsolete Identifiers: NCT00711334
Other Study ID Numbers: CDR0000579579, P50CA058204, BCM-H-17274, BCM-SPORE-11-01-30-14
Study First Received: February 14, 2008
Last Updated: November 5, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Baylor College of Medicine:
recurrent prostate cancer
stage IV prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
 Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on May 16, 2013